Forte Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Net Income	-51.74	-35.48	-31.48	-13.88	-21.71	-46.49
Depreciation & Amortization	0.06	0.04	0.01	-	0.04	0.05
Asset Writedown & Restructuring Costs	-	-	-	-	0.06	30.89
Loss (Gain) From Sale of Investments	-0.4	-0.16	-0.13	-	-	-
Stock-Based Compensation	5.29	3.1	3.28	4.01	4.21	0.96
Change in Accounts Payable	0.33	3.02	0.27	0.21	-0.29	-0.37
Change in Other Net Operating Assets	2.04	-1.26	-0.66	1.47	1.01	-3.46
Operating Cash Flow	-44.43	-30.75	-28.71	-8.19	-16.68	-18.42
Capital Expenditures	-0.15	-0.04	-0.09	-	-	-
Cash Acquisitions	-	-	-	-	-	3.58
Investment in Securities	0.39	-35.96	0.14	-	-	-
Investing Cash Flow	0.25	-35.99	0.05	-	-	3.58
Issuance of Common Stock	129.82	53.01	25.02	7.24	0.06	66.96
Repurchase of Common Stock	-0.03	-0.04	-0.06	-	-	-
Other Financing Activities	-8.56	-1.12	-0.27	-	-0.11	-0.29
Financing Cash Flow	121.23	51.86	24.68	7.24	-0.04	66.67
Net Cash Flow	77.05	-14.88	-3.98	-0.94	-16.72	51.83
Free Cash Flow	-44.57	-30.78	-28.79	-8.19	-16.68	-18.42
Free Cash Flow Per Share	-3.78	-10.56	-22.80	-11.77	-29.85	-62.59
Levered Free Cash Flow	-24.48	-16.14	-17.4	-3.18	-9.02	-8.1
Unlevered Free Cash Flow	-24.48	-16.14	-17.4	-3.18	-9.02	-8.1
Change in Working Capital	2.37	1.76	-0.39	1.68	0.72	-3.83

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q